15 results about "Pulmonary inhalation" patented technology

Disclosed herein are stable solution, suspension and dry powder compositions, and methods for delivering stabilized biodegradable substances, including peptides and proteins, small molecules, and methods for delivering the dry powders in the treatment of lung disease. In particular, the compositions comprise vasoactive intestinal peptide for pulmonary inhalation to treat respiratory disorders and / or diseases in the lung, including, inflammation, acute and chronic lung injury and pulmonary edema.

The application discloses a compound inhalation powder aerosol and a preparation method thereof. The compound inhalation powder aerosol comprises apremilast or a pharmaceutically acceptable salt thereof and an efficacy enhancing substance, wherein the efficacy enhancing substance is nintedanib or a pharmaceutically acceptable salt thereof; and the amount of the efficacy enhancing substance is 0.1-10 times the amount of the apremilast or the pharmaceutically acceptable salt thereof. In the compound inhalation powder aerosol, the drug exposure of apremilast is greatly improved under the action of nintedanib, and a significant enhancement effect is exhibited. Meanwhile, nintedanib further improves efficacy. The powder aerosol is used for pulmonary inhalation administration, and apremilast or the pharmaceutically acceptable salt thereof and nintedanib or the pharmaceutically acceptable salt thereof are used for treating lung diseases, so that the drugs can be directly delivered to effective sites, the administration dose can be further effectively reduced or the drug utilization rate can be improved, the deposition rate can be improved, and the treatment effect can be greatly improved.

The application belongs to the field of nucleic acid drug delivery, and mainly relates to a glycerophosphoryl ethanolamine skeleton compound and a lipid nano drug carrier comprising the same. The glycerophosphoryl ethanolamine skeleton compound has a structure as shown in formula (I): The application modifies a dithiolane structure at the phosphate hydrophilic end of a glycerophosphoryl ethanolamine lipid, so that the dithiolane structure is more fully exposed on the surface of LNP, so that more dithiolane is exposed on the surface of the prepared LNP, and the endocytosis of mucosal cells to LNP can be further promoted. The glycerophosphoryl ethanolamine skeleton compound has a wide adjustment range in the LNP prescription, and can increase the content of dithiolane in LNP. The nucleic acid lipid nanoparticle composition and the pharmaceutical preparation provided by the application can be used for ocular delivery, pulmonary inhalation delivery and nasal spray of nucleic acid drugs, and provide a new choice for extrahepatic delivery of nucleic acid drugs.

The utility model discloses a chronic obstructive pulmonary inhalant auxiliary device convenient to use, and relates to the technical field of chronic obstructive pulmonary inhalant assistance. A placement groove, an abutting cavity, an operation cavity, a ventilation cavity and a mounting cavity are formed in the equipment shell, an equipment switch is arranged at the front side end of the equipment shell, a spray bottle and a connector are arranged in the placement groove, an abutting mechanism is arranged in the abutting cavity, and a spray pressing mechanism is arranged on the inner side of the operation cavity. When the device is used, the device switch is pressed, the medicine spraying pressing mechanism is utilized to extrude the spray bottle, sprayed medicine is guided into the mouth of a patient from the medicine guiding pipe and the imbedding pipe, manual pressing operation of the patient is not needed, medicine spraying operation can be achieved only by clicking the device switch, and the device can be easily used by the patient even with poor hand-mouth coordination. Meanwhile, the micro air pump is used for blowing air into the gap between the vent hole and the medicine guide tube, so that the medicine can be effectively delivered to the lung even if the inspiration force of the patient is insufficient, and the treatment effect is ensured.

The present invention provides a process for micronizing and conditioning crystalline indacaterol acetate which yields a micronized product containing low content of amorphous form. The invention also refers to crystalline micronized indacaterol acetate obtained by the process of the invention for use in pharmaceutical compositions for pulmonary inhalation for the treatment of asthma.

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention provides a preparation method of a lung inhalation microsphere carrying rifapentine, which comprises the following steps: weighing a biodegradable high-molecular polymer and rifapentine, and dissolving the biodegradable high-molecular polymer and the rifapentine in a low-boiling-point organic solvent to form an oil phase; weighing a stabilizer, and dissolving the stabilizer in pure water to form a water phase; slowly dropwise adding the oil phase into the water phase, and stirring and emulsifying at a high speed for 1-30 minutes to form an emulsion; lowering the stirring speed, and continuously stirring for 1-24 hours at a uniform speed until the organic solvent is completely volatilized; carrying out low-speed centrifugation on the residual solution for 1-10 minutes, collecting sustained-release microspheres prepared at the bottom of the solution, then washing the centrifugal microspheres with purified water, and repeating for three times; and freeze-drying a solid product obtained by centrifugation to obtain the microspheres. The production process is simple, the prepared drug-loaded microspheres can accurately deliver drugs to the lung, the drugs can be concentrated at a target site and slowly released after being administered, the maintenance time of the effective concentration of the drugs in local tissues is prolonged, and the compliance of patients is improved.

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of dry powder, and processes for their preparation. In addition, the present invention provides a pharmaceutical combination comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided herein are useful for the treatment and / or prevention of pulmonary fungal infections and pulmonary infections caused by mycobacteria and other gram-positive bacteria.

The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and / or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention discloses a bacillus cereus inhalant and application of the bacillus cereus inhalant in treatment of pulmonary fibrosis. After the pulmonary administration of the bacillus cereus inhalant, more bacillus cereus exist in the lung, the bacillus cereus secretes collagenase, and the collagenase degrades collagen in fibrotic tissues, so that the pulmonary fibrosis resisting effect is achieved. After pulmonary fibrosis model animals inhale the bacillus cereus inhalant, the respiratory function and the athletic ability are greatly improved, the respiratory function and the athletic ability are remarkably different from those of non-administrated model animals in the aspects of lung tissue appearance, collagen deposition, the inflammatory factor level and the hydroxyproline level, and part of indexes are close to those of healthy animals.

The invention belongs to the technical field of biological medicines, and particularly relates to acacetin-containing lipid nanoparticles for a pulmonary inhalation type mRNA vaccine as well as a preparation method and application of the acacetin-containing lipid nanoparticles. The lipid nano-particle takes acacetin as a functional fifth component, is jointly composed of ionized lipid, neutral auxiliary lipid, cholesterol and polyethylene glycol lipid, and can effectively wrap mRNA (messenger Ribonucleic Acid) of an encoding antigen. According to the preparation method, high-efficiency compounding of lipid and mRNA is realized through a microfluidic technology, the particle size of the obtained particles is adaptive to lung targeting, alveolar macrophage removal can be reduced, mRNA is protected from peroxidation damage, and vaccine response is enhanced through the immunomodulatory effect of acacetin. The system can be prepared into a lung inhalation type mRNA vaccine, is used for preventing and controlling respiratory tract infectious diseases, has high-efficiency delivery, strong immunization and good safety, and provides a new scheme for construction of a lung immune barrier.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.

The application provides a live heart pill liposome aerosol and a preparation method and application thereof, the live heart pill liposome aerosol comprising drug-loaded liposomes, a propellant and a cosolvent; the drug-loaded liposomes comprise core materials and wall materials; the mass ratio of the core materials to the wall materials is 1:(5-11); the core materials comprise traditional Chinese medicine active ingredients; the wall materials comprise neutral lipids, anionic lipids and sterols; the traditional Chinese medicine active ingredients comprise 400-600 parts of ginseng, 150-300 parts of ox gall, 50-150 parts of ganoderma lucidum, 15-50 parts of pearls, 2-10 parts of aconite, 20-100 parts of safflower, 2-20 parts of musk, 5-15 parts of bear gall, 4-20 parts of toad venom and 2-10 parts of borneol in terms of weight parts. The live heart pill liposome aerosol of the application is administered through pulmonary inhalation, has a quick effect after administration and is obviously superior to an oral dosage form, and can better meet the timeliness requirement of first-aid medicines in the acute attack of angina pectoris.

A process for manufacturing a Treprostinil-diketopiperazine dry powder for pharmaceutical use by spray drying a suspension without need to dissolve Treprostinil in an alcohol solution prior to processing. In some embodiments, the dry powder is for oral inhalation for pulmonary delivery using a dry powder inhaler.

The present application relates to the technical field of pharmaceutical preparation, in particular to a kind of inhalable drug-loaded nanoparticles and its preparation method and application.The drug-loaded nanoparticles include polymer nanocarriers, and nintedanib loaded on the polymer nanocarriers by hydrogen bond;The polymer nanocarriers are obtained by self-assembly of cationic polysaccharide and anionic polymer through electrostatic interaction.Cationic polysaccharide and anionic polymer form polymer nanocarriers with stable internal structure through electrostatic interaction, which can significantly improve the encapsulation efficiency of nintedanib.The drug-loaded nanoparticles prepared by ion crosslinking method have uniform particle size, good bioavailability and sustained-release therapeutic effect, and can be used as a powerful choice for treating idiopathic pulmonary fibrosis by pulmonary inhalation preparation.